Use of obinutuzumab in clinical practice – case report


MUDr. Mária Maco

Interní hematologická klinika 3. LF UK a FNKV, Praha



Obinutuzumab with bendamustine is currently used for the treatment of follicular lymphoma in patients who are refractory to rituximab alone or to combination of chemotherapy with rituximab. This case report describes a successful treatment with obinutuzumab and bendamustine followed by obinutuzumab maintenance in a patient with multiple relapses of follicular lymphoma after several treatment lines with rituximab.


Key words

follicular lymphoma, obinutuzumab, bendamustine, refractory lymphoma



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...